<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066920</url>
  </required_header>
  <id_info>
    <org_study_id>IBER</org_study_id>
    <nct_id>NCT04066920</nct_id>
  </id_info>
  <brief_title>IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL</brief_title>
  <official_title>Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deok-Hwan Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, single-arm, prospective phase II study to evaluate the efficacy and
      safety of a novel combination regimen for relapsed/refractory PCNSL. Specifically, ibrutinib
      will be administered in combination with ifosfamide, etoposide and rituximab (IBER) as a
      salvage chemotherapy, which is followed by maintenance ibrutinib monotherapy of fixed
      duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given the limited activity of salvage therapy with high-dose methotrexate re-treatment and/or
      alkylator-based treatment in patients with relapse or refractory PCNSL, the development of
      novel salvage chemotherapy regimen remains an area of clinical unmet need.

      Ibrutinib, an oral inhibitor of bruton tyrosine kinase (BTK), is known to induce death of
      diffuse large B-cell lymphoma (DLBCL) cells with dysregulated B-cell receptor (BCR) signaling
      and has shown promising activity in patients with a variety of B-cell malignancies. Recently,
      several studies reported that ibrutinib may have an excellent single-agent clinical activity
      against relapsed or refractory PCNSL. Furthermore, proven pharmacokinetic data suggested that
      ibrutinib successfully penetrated the BBB and reached the achievable concentration in
      cerebrospinal fluid. When ibrutinib is administered in combination with BBB-destructing
      chemotherapeutic agents (such as, temozolomide or etoposide) for salvage treatment of PCNSL,
      therefore, anti-lymphoma activity of ibrutinib could be maximized.

      In this context, this phase II study is designed to evaluate the efficacy and safety of IBER
      salvage chemotherapy followed by ibrutinib maintenance for transplant ineligible patients
      with relapsed or refractory PCNSL.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>From date of starting the study treatment until the date of finishing the study treatment for any reason, assessed up to 10 months</time_frame>
    <description>The percentage of patients with a complete response (CR) or a partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the study treatment</measure>
    <time_frame>From the first day of the first cycle of IBER induction chemotherapy to 30 days after the last dose of study drug, assessed up to 12 months</time_frame>
    <description>Treatment-emergent adverse events graded according to the NCI-CTCAC version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>IBER treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the only arm in a single-arm phase II study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBER salvage chemotherapy followed by ibrutinib maintenance therapy</intervention_name>
    <description>Induction therapy with IBER (up to 6 cycles) [ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 ], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months</description>
    <arm_group_label>IBER treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed PCNSL of CD20+ diffuse large B cell lymphoma (DLBCL)

          -  PCNSL relapsed or refractory after frontline methotrexate-based chemotherapy (with or
             without radiation therapy)

          -  At least one measurable lesion, which is defined as longest diameter of lesion &gt; 0.5
             cm, by contrast-enhanced MRI

          -  ECOG performance status 0-2

          -  Normal function of major organs

        Exclusion Criteria:

          -  PCNSL other than DLBCL

          -  Primary ocular lymphoma

          -  PCNSL accompanied by systemic involvement

          -  Active infection with hepatitis B or C virus

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Therapy with myelosuppressive chemotherapy or biologic therapy &lt; 21 days prior to
             registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deok-Hwan Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deok-Hwan Yang, M.D., Ph.D.</last_name>
    <phone>+82-61-379-7636</phone>
    <email>drydh1685@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoon Seok Choi, M.D., Ph.D.</last_name>
    <phone>+82-42-280-7107</phone>
    <email>wyfran@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011 Oct 25;105(9):1414-8. doi: 10.1038/bjc.2011.357. Epub 2011 Sep 13.</citation>
    <PMID>21915121</PMID>
  </reference>
  <reference>
    <citation>Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol. 2003 Jun 15;21(12):2407-14.</citation>
    <PMID>12805341</PMID>
  </reference>
  <reference>
    <citation>Reni M, Mazza E, Foppoli M, Ferreri AJ. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate. Cancer Lett. 2007 Dec 18;258(2):165-70. Epub 2007 Nov 13. Review.</citation>
    <PMID>17993246</PMID>
  </reference>
  <reference>
    <citation>Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, Korfel A. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006 Jul;17(7):1141-5. Epub 2006 Apr 7.</citation>
    <PMID>16603598</PMID>
  </reference>
  <reference>
    <citation>Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007 Mar 26;96(6):864-7. Epub 2007 Feb 27.</citation>
    <PMID>17325700</PMID>
  </reference>
  <reference>
    <citation>Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20.</citation>
    <PMID>26193343</PMID>
  </reference>
  <reference>
    <citation>Vater I, Montesinos-Rongen M, Schlesner M, Haake A, Purschke F, Sprute R, Mettenmeyer N, Nazzal I, Nagel I, Gutwein J, Richter J, Buchhalter I, Russell RB, Wiestler OD, Eils R, Deckert M, Siebert R. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015 Mar;29(3):677-85. doi: 10.1038/leu.2014.264. Epub 2014 Sep 5.</citation>
    <PMID>25189415</PMID>
  </reference>
  <reference>
    <citation>Braggio E, McPhail ER, Macon W, Lopes MB, Schiff D, Law M, Fink S, Sprau D, Giannini C, Dogan A, Fonseca R, O'Neill BP. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res. 2011 Jul 1;17(13):4245-53. doi: 10.1158/1078-0432.CCR-11-0395. Epub 2011 May 11.</citation>
    <PMID>21562036</PMID>
  </reference>
  <reference>
    <citation>Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.</citation>
    <PMID>20054396</PMID>
  </reference>
  <reference>
    <citation>Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.</citation>
    <PMID>28619981</PMID>
  </reference>
  <reference>
    <citation>Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25.</citation>
    <PMID>28552327</PMID>
  </reference>
  <reference>
    <citation>Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011 Mar 8;76(10):929-30. doi: 10.1212/WNL.0b013e31820f2d94.</citation>
    <PMID>21383331</PMID>
  </reference>
  <reference>
    <citation>Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol. 2013 Sep;31(3):143-50. doi: 10.1002/hon.2037. Epub 2012 Nov 14.</citation>
    <PMID>23161567</PMID>
  </reference>
  <reference>
    <citation>Birnbaum T, Stadler EA, von Baumgarten L, Straube A. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol. 2012 Sep;109(2):285-91. doi: 10.1007/s11060-012-0891-7. Epub 2012 May 9.</citation>
    <PMID>22570142</PMID>
  </reference>
  <reference>
    <citation>Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol. 2003 Apr;70(4):219-24.</citation>
    <PMID>12656744</PMID>
  </reference>
  <reference>
    <citation>Küker W, Nägele T, Thiel E, Weller M, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology. 2005 Oct 11;65(7):1129-31.</citation>
    <PMID>16217075</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Deok-Hwan Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

